Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

221. Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA (Abstract)

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA Purpose In patients with metastatic castration-resistant prostate cancer (mCRPC), overall survival (OS) is significantly improved with cabazitaxel versus mitoxantrone after prior docetaxel treatment. FIRSTANA ( ClinicalTrials.gov identifier: NCT01308567) assessed whether cabazitaxel 20 mg/m2 (C20) or 25 mg/m2 (C25) is superior to docetaxel (...) 75 mg/m2 (D75) in terms of OS in patients with chemotherapy-naïve mCRPC. Patients and Methods Patients with mCRPC and Eastern Cooperative Oncology Group performance status of 0 to 2 were randomly assigned 1:1:1 to receive C20, C25, or D75 intravenously every 3 weeks plus daily prednisone. The primary end point was OS. Secondary end points included safety; progression-free survival (PFS); tumor, prostate-specific antigen, and pain response; pharmacokinetics; and health-related quality of life

2017 EvidenceUpdates

222. eUpdate ? Cancer of the Prostate Treatment Recommendations

Bronchial and Thymic Tumours • Neuroendocrine Gastroenteropancreatic Tumours • Adrenal Cancer • Thyroid Cancer Gastrointestinal Cancers Rectal Cancer • Biliary cancer • Gastric cancer • Oesophageal cancerCancer of the pancreas • Metastatic colorectal cancer • Anal cancer • Early colon cancer • Familial risk colorectal cancer • Hepatocellular carcinoma Genitourinary Cancers Testicular Germ Cell CancerCancer of the Prostate • Bladder Cancer • Renal Cell Carcinoma • Penile Carcinoma • Testicular (...) Seminoma and Non-Seminoma Gynaecological Cancers Cervical cancer • Endometrial cancer • Gestational trophoblastic disease • Newly diagnosed and relapsed epithelial ovarian carcinoma • Non-epithelial ovarian cancer Haematological Malignancies Waldenstrom's macroglobulinaemia • Chronic myeloid leukaemia • Newly diagnosed and relapsed mantle cell lymphoma • Multiple myeloma • Newly diagnosed and relapsed follicular lymphoma • Extranodal diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma

2017 European Society for Medical Oncology

223. Prostate cancer patient perspectives on the use of information in treatment decision-making: a systematic review and qualitative meta-synthesis

Prostate cancer patient perspectives on the use of information in treatment decision-making: a systematic review and qualitative meta-synthesis Prostate cancer patient perspectives on the use of information in treatment decision-making: a systematic review and qualitative meta-synthesis Prostate cancer patient perspectives on the use of information in treatment decision-making: a systematic review and qualitative meta-synthesis Health Quality Ontario Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Quality Ontario. Prostate cancer patient perspectives on the use of information in treatment decision-making: a systematic review and qualitative meta-synthesis. Toronto: Health Quality Ontario (HQO). Ontario health technology assessment series; 17(7). 2017 Authors' conclusions Although each prostate cancer patient is unique, studies suggest

2017 Health Technology Assessment (HTA) Database.

224. Prolaris cell cycle progression test for localized prostate cancer: OHTAC Recommendation

Prolaris cell cycle progression test for localized prostate cancer: OHTAC Recommendation Prolaris cell cycle progression test for localized prostate cancer: OHTAC Recommendation Prolaris cell cycle progression test for localized prostate cancer: OHTAC Recommendation Ontario Health Technology Advisory Committee (OHTAC) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Ontario Health Technology Advisory Committee (OHTAC). Prolaris cell cycle progression test for localized prostate cancer: OHTAC Recommendation. Toronto: Health Quality Ontario (HQO). 2017 Authors' conclusions After considering the available evidence on clinical utility, budget impact, and lived experience, as well as patient preferences and values, the committee reached consensus that there is uncertainty about the potential clinical benefits of this test. The clinical

2017 Health Technology Assessment (HTA) Database.

225. Prolaris cell cycle progression test for localized prostate cancer: a health technology assessment

to clinical risk stratification, may change the treatment plan or actual treatment for some low- and intermediate-risk prostate cancer patients. As a result, there is insufficient data to inform the cost-effectiveness of the CCP test. Publicly funding the CCP test would result in a large incremental cost to the provincial budget. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Cell Division; Humans; Male; Prostatic Neoplasms; Technology Assessment, Biomedical Language Published (...) Prolaris cell cycle progression test for localized prostate cancer: a health technology assessment Prolaris cell cycle progression test for localized prostate cancer: a health technology assessment Prolaris cell cycle progression test for localized prostate cancer: a health technology assessment Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made

2017 Health Technology Assessment (HTA) Database.

226. Comparative effectiveness review of cryoablation for primary treatment of localized prostate cancer

options for localized prostate cancer; however, questions remain about the long-term efficacy for local and distant tumor control and survival. Relevant Questions: Does cryoablation provide effective local tumor control and acceptable rates of remission and long-term disease-free survival in patients with primary localized prostate cancer? Does cryoablation provide acceptable outcomes with regard to patient-reported outcomes, including quality of life, urinary function, prostate symptoms, and sexual (...) who prefer a less invasive option than prostatectomy or who are not appropriate surgical candidates. Rationale: The goals of the minimally invasive cryoablation treatment for localized prostate cancer are to use focused cryoablation energy to ablate the entire prostate gland or the cancer-containing part of the gland and achieve complete tumor control to improve survival. Controversy: Locally ablative therapies such as cryoablation may have less morbidity compared with other primary treatment

2017 Health Technology Assessment (HTA) Database.

227. MR guided biopsy procedures for diagnosis of prostate cancer

) or transperineal ultrasound guided biopsy (TPUSGB) using software fusion of previously acquired mpMRI images and ultrasound images. This method provides real-time ultrasound guidance but does not allow validation of the track of the biopsy needle through the identified mpMRI lesion as the MRI image is not live. MSAC noted that the application proposed these procedures would be used exclusively for the diagnosis of prostate cancer in patients who are likely to be at intermediate/high risk of the disease. MSAC (...) Intervention 2:MR-US fusion $36,213 -$72 8.11 ~0.005 Dominant b 14 ICER = Incremental Cost Effectiveness Ratio; MR = magnetic resonance; PCa = prostate cancer; US = ultrasound; QALY = quality- adjusted life year a Differences in ICER due to rounding from TreeAge Pro 2015 b Albeit marginal gain in QALYs The model was sensitive to the cost of TPUSGB, the assumption of a disutility for biopsy, the assumption of disease upgrading for false negatives was high and favoured MR-US fusion and MR-in gantry

2017 Medical Services Advisory Committee

228. Enzalutamide (Xtandi) for non-metastatic prostate cancer

Enzalutamide (Xtandi) for non-metastatic prostate cancer Enzalutamide (Xtandi) for non-metastatic prostate cancer | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required (...) for our stakeholders. > > > Enzalutamide (Xtandi) for non-metastatic prostate cancer Enzalutamide (Xtandi) for non-metastatic prostate cancer September 2017 Enzalutamide (Xtandi) is a drug which blocks the effect of the hormone testosterone on the prostate and so slows down the growth of the cancer. Enzalutamide is taken as four capsules once a day. If licenced in the UK, it could provide an additional treatment option for patients with non-metastatic prostate cancer Innovation Observatory Voice Leave

2017 NIHR Innovation Observatory

229. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Full Text available with Trip Pro

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. The ERSPC (European Randomized Study of Screening for Prostate Cancer) found that screening reduced prostate cancer mortality, but the PLCO (Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial) found no reduction.To evaluate whether effects of screening on prostate cancer mortality relative to no screening differed between the ERSPC and PLCO.Cox regression of prostate cancer death in each (...) trial group, adjusted for age and trial. Extended analyses accounted for increased incidence due to screening and diagnostic work-up in each group via mean lead times (MLTs), which were estimated empirically and using analytic or microsimulation models.Randomized controlled trials in Europe and the United States.Men aged 55 to 69 (ERSPC) or 55 to 74 (PLCO) years at randomization.Prostate cancer screening.Prostate cancer incidence and survival from randomization; prostate cancer incidence

2017 Annals of Internal Medicine

230. Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline (Abstract)

at improving bone health or outcomes such as skeletal-related events, pain and quality of life in patients with prostate cancer either with or without metastases to bone. Therapies included medications, supplements or lifestyle modifications alone or in combination and were compared with placebo, no treatment or other agents. Disease-targeted agents such as androgen receptor-targeted and chemotherapeutic agents were excluded. Recommendations were reviewed by internal and external review groups.In men (...) Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline To make recommendations with respect to bone health and bone-targeted therapies in men with prostate cancer.A systematic review was carried out by searching MEDLINE, EMBASE and the Cochrane Library from inception to January 2016. Systematic reviews and randomised-controlled trials were considered for inclusion if they involved therapies directed

2017 EvidenceUpdates

231. Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer

Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer Biodegr Biodegradable spacer insertion to reduce rectal adable spacer insertion to reduce rectal to toxicity during r xicity during radiother adiotherap apy for prostate cancer y for prostate cancer Interventional procedures guidance Published: 23 August 2017 nice.org.uk/guidance/ipg590 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after careful (...) Recommendations 1.1 Current evidence on the safety and efficacy of insertion of a biodegradable spacer to reduce rectal toxicity during radiotherapy for prostate cancer is adequate to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent and audit. © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 81.2 The procedure should only be done by clinicians

2017 National Institute for Health and Clinical Excellence - Interventional Procedures

232. A Patient (46XX) With Congenital Adrenal Hyperplasia and Prostate Cancer: A Case Report Full Text available with Trip Pro

A Patient (46XX) With Congenital Adrenal Hyperplasia and Prostate Cancer: A Case Report Congenital adrenal hyperplasia (CAH) can affect sex characteristics. The most common cause of CAH is 21-hydroxylase deficiency, and the cornerstone of treatment is glucocorticoid replacement in adrenocorticotropic hormone-suppressive dosages. A 64-year-old patient (46XX) with CAH resulting from 21-hydroxylase deficiency had been treated with dexamethasone and testosterone since diagnosis at age 12 (...) and was phenotypically male. At age 62, he was diagnosed with prostate carcinoma. The patient received curative treatment with external beam radiotherapy. Genotypically female patients with CAH can develop prostate carcinoma when receiving long-term testosterone replacement therapy.

2017 Journal of the Endocrine Society

233. Outcomes and toxicity of 313 prostate cancer patients receiving helical tomotherapy after radical prostatectomy Full Text available with Trip Pro

Outcomes and toxicity of 313 prostate cancer patients receiving helical tomotherapy after radical prostatectomy There are limited long-term data on patients treated with image guided intensity modulated radiation therapy (IG-IMRT) for prostate cancer recurrence or high-risk disease features after radical prostatectomy. We report single-institution results for patients treated with IG-IMRT and identify variables associated with outcome.This is a retrospective chart review consisting of 313 (...) consecutive patients who were treated with adjuvant or salvage IG-IMRT from 2004 to 2013. Cox proportional hazards analysis was used to identify factors related to survival and toxicity. Toxicity was graded using the Common Terminology Criteria for Adverse Events Version 4.0.The median follow-up was 55 months (range, 6-131 months). The median pre-radiation therapy (RT) prostate-specific antigen (PSA) was 0.3 ng/mL (range, <0.01-55.4). The vast majority of patients (87%) received elective pelvic nodal

2017 Advances in radiation oncology

234. Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408 Full Text available with Trip Pro

Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408 We reviewed testosterone changes for patients who were treated with radiation therapy (RT) alone on NRG oncology RTOG 9408.Patients (T1b-T2b, prostate-specific antigen <20 ng/mL) were randomized between RT alone and RT plus 4 months of androgen ablation. Serum testosterone (ST) levels were investigated at enrollment, RT completion, and the first follow-up 3 months after RT (...) , respectively, were analyzed. For all patients, the median change in ST values at completion of RT and at 3-month follow-up were -30.0 ng/dL (p5-p95; -270.0 to 162.0; P < .001) and -34.0 ng/dL (p5-p95, -228.0 to 160.0; P < .01), respectively.RT for prostate cancer was associated with a median 9.2% decline in ST at completion of RT and a median 9.3% decline 3 months after RT. These changes were statistically significant.

2017 Advances in radiation oncology Controlled trial quality: uncertain

235. Second-Line Hormonal Therapy for Men With Chemotherapy-Naive, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion Full Text available with Trip Pro

Second-Line Hormonal Therapy for Men With Chemotherapy-Naive, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion Purpose ASCO provisional clinical opinions (PCOs) offer direction to the ASCO membership after publication or presentation of potential practice-changing data. This PCO addresses second-line hormonal therapy for chemotherapy-naïve men with castration-resistant prostate cancer (CRPC) who range from being asymptomatic with only (...) opinion inform this PCO. Provisional Clinical Opinion For men with CRPC, a castrate state should be maintained indefinitely. Second-line hormonal therapy (eg, antiandrogens, CYP17 inhibitors) may be considered in patients with nonmetastatic CRPC at high risk for metastatic disease (rapid prostate-specific antigen doubling time or velocity) but otherwise is not suggested. In patients with radiographic evidence of metastases and minimal symptoms, enzalutamide or abiraterone plus prednisone should

2017 EvidenceUpdates

236. Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy Full Text available with Trip Pro

Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy Urothelial prostatic involvement (UPI) at the time of radical cystoprostatectomy (RCP) was found associated with worse survival outcomes by several previous reports. Our aim is to evaluate the impact of different levels of UPI on survival outcomes using a large series of male patients treated with RCP.Whole step section specimens from 995 male BCa patients were assessed for UPI defined (...) as: no involvement vs. prostatic urethral carcinoma in situ (CIS) vs. lamina propria involvement vs. ductal CIS vs. prostate stromal involvement. Primary end point of the study was predictors of prostatic involvement at RCP and its impact on overall survival after surgery.Prostatic involvement was recorded in 307 (30.9%) patients: 28% with prostatic urethral CIS, 12% with lamina propria involvement, 13% with ductal CIS and 47% with stromal involvement. Median follow-up was 70 months. Patients with stromal

2017 Bladder cancer (Amsterdam, Netherlands)

237. Editorial Concerning “Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy” Full Text available with Trip Pro

Editorial Concerning “Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy” 28824944 2019 01 15 2352-3727 3 3 2017 Jul 27 Bladder cancer (Amsterdam, Netherlands) Bladder Cancer Editorial Concerning "Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy". 171-172 10.3233/BLC-179017 Shen Steven S Professor of Pathology and Laboratory Medicine, Associate Director of Surgical Pathology (...) , Department of Pathology and Genomic Medicine, Houston Methodist Hospital and Weill Medical College of Cornell University. Lerner Seth P SP Professor and Beth and Dave Swalm Chair in Urologic Oncology, Director of Urologic Oncology, Scott Department of Urology, Baylor College of Medicine. eng Editorial 2017 07 27 Netherlands Bladder Cancer 101668567 2017 8 22 6 0 2017 8 22 6 0 2017 8 22 6 1 epublish 28824944 10.3233/BLC-179017 BLC179017 PMC5545913 Eur Urol. 2008 Feb;53(2):370-5 17689003 Expert Rev

2017 Bladder cancer (Amsterdam, Netherlands)

238. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. Full Text available with Trip Pro

August 2014 for our primary outcome, all-cause mortality, and the main secondary outcome, prostate-cancer mortality. We describe disease progression, treatments received, and patient-reported outcomes through January 2010 (original follow-up).During 19.5 years of follow-up (median, 12.7 years), death occurred in 223 of 364 men (61.3%) assigned to surgery and in 245 of 367 (66.8%) assigned to observation (absolute difference in risk, 5.5 percentage points; 95% confidence interval [CI], -1.5 to 12.4 (...) ; hazard ratio, 0.84; 95% CI, 0.70 to 1.01; P=0.06). Death attributed to prostate cancer or treatment occurred in 27 men (7.4%) assigned to surgery and in 42 men (11.4%) assigned to observation (absolute difference in risk, 4.0 percentage points; 95% CI, -0.2 to 8.3; hazard ratio, 0.63; 95% CI, 0.39 to 1.02; P=0.06). Surgery may have been associated with lower all-cause mortality than observation among men with intermediate-risk disease (absolute difference, 14.5 percentage points; 95% CI, 2.8 to 25.6

2017 NEJM Controlled trial quality: predicted high

239. Initiative to reduce bone scans for low-risk prostate cancer patients: A quasi-experimental before-and-after study in a Veterans Affairs hospital Full Text available with Trip Pro

Initiative to reduce bone scans for low-risk prostate cancer patients: A quasi-experimental before-and-after study in a Veterans Affairs hospital Bone scans (BS) are a low-value test for asymptomatic men with low-risk prostate cancer. We performed a quality improvement intervention aimed at reducing BS for these patients.The intervention was a presentation that leveraged the behavioral science concepts of social comparison and normative appeals. Participants were multidisciplinary stakeholders (...) from the Radiation Oncology and Urology services at a Veterans Affairs hospital. We determined the baseline rate of BS by retrospectively analyzing cases of asymptomatic men with newly diagnosed low-risk prostate cancer. For social comparison, we presented contemporary peer BS rates in the United States-including Veterans Affairs hospitals. For normative appeals, we reviewed guidelines from various professional groups. To analyze the effect of this intervention, we performed a quasi-experimental

2017 Advances in radiation oncology

240. Efficacy of Blended Cognitive Behavior Therapy for High Fear of Recurrence in Breast, Prostate, and Colorectal Cancer Survivors: The SWORD Study, a Randomized Controlled Trial (Abstract)

Efficacy of Blended Cognitive Behavior Therapy for High Fear of Recurrence in Breast, Prostate, and Colorectal Cancer Survivors: The SWORD Study, a Randomized Controlled Trial Purpose Fear of cancer recurrence (FCR) is a common problem experienced by cancer survivors. Approximately one third of survivors report high FCR. This study aimed to evaluate whether blended cognitive behavior therapy (bCBT) can reduce the severity of FCR in cancer survivors curatively treated for breast, prostate (...) , or colorectal cancer. Patients and Methods This randomized controlled trial included 88 cancer survivors with high FCR (Cancer Worry Scale score ≥ 14) from 6 months to 5 years after cancer treatment. Participants were randomly allocated (ratio 1:1, stratified by cancer type) to receive bCBT, including five face-to face and three online sessions (n = 45) or care as usual (CAU; n = 43). Participants completed questionnaires at baseline (T0) and 3 months later (T1). The intervention group completed bCBT

2017 EvidenceUpdates